Pneumococcal Vaccine Global Market Report 2026

Description

The pneumococcal vaccine is an immunization that provides protection against serious and potentially life-threatening pneumococcal infections caused by Streptococcus pneumoniae, including pneumonia, meningitis, and sepsis. It is highly effective in safeguarding infants against one of the leading causes of meningitis and other illnesses, such as acute ear infections.

The primary pneumococcal vaccines include Prevnar 13, Synflorix, Pneumovax 23, and others. Prevnar 13 is a pneumococcal conjugate vaccine that contains 13 different strains of Streptococcus pneumoniae and is used in children as well as tested in immunocompromised patients to prevent pneumococcal disease. These vaccines are administered through routes such as intravenous, intramuscular, and subcutaneous injection and are distributed through pharmacies, community clinics, public health agencies, and other channels for use by pediatric and adult populations.

Tariffs have influenced the pneumococcal vaccine market by increasing the cost of imported biologics, active ingredients, and cold-chain packaging materials, thereby impacting overall vaccine pricing and procurement budgets. The effects are most visible in conjugate vaccine segments and in regions reliant on imports such as parts of asia-pacific, latin america, and africa. Public immunization programs face budgetary pressure, while manufacturers experience margin constraints. However, tariffs have also encouraged local manufacturing, technology transfer, and regional production hubs, supporting long-term supply resilience and self-sufficiency.

The pneumococcal vaccine market research report is one of a series of new reports from The Business Research Company that provides pneumococcal vaccine market statistics, including pneumococcal vaccine industry global market size, regional shares, competitors with a pneumococcal vaccine market share, detailed pneumococcal vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the pneumococcal vaccine industry. This pneumococcal vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pneumococcal vaccine market size has grown strongly in recent years. It will grow from $9.4 billion in 2025 to $9.94 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to high childhood pneumonia burden, inclusion in national immunization programs, strong support from global health organizations, rising awareness of invasive pneumococcal disease, proven efficacy of pcv vaccines.

The pneumococcal vaccine market size is expected to see strong growth in the next few years. It will grow to $12.76 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to launch of next-generation pcv vaccines, expanding adult vaccination recommendations, growth in healthcare access in emerging economies, increasing antimicrobial resistance concerns, government funding for preventive immunization. Major trends in the forecast period include expansion of conjugate vaccines for broader serotype coverage, increased focus on pediatric and geriatric immunization programs, rising adoption of combination and booster vaccination strategies, strengthening public-private partnerships for immunization coverage, growth in preventive healthcare and national immunization schedules.

The rising prevalence of pneumococcal infections is expected to drive the growth of the pneumococcal vaccine market in the coming years. Pneumococcal infection refers to illnesses caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus, including conditions such as pneumonia, bloodstream infections, ear infections, and sinus infections. Pneumococcal vaccines work by stimulating the immune system to produce antibodies against pneumococcal bacteria, helping to reduce or eliminate disease-causing bacteria and toxins and protecting vulnerable populations such as children, older adults, and individuals with weakened immune systems from various pneumococcal diseases. For instance, in July 2025, according to the Immunisation Coalition, an Australia-based independent not-for-profit organization, reported cases of invasive pneumococcal disease (IPD) increased consistently over recent years, rising from 1,869 cases in 2022 to 2,265 in 2023 and reaching 2,379 cases in 2024. Therefore, the growing prevalence of pneumococcal infections is contributing to the expansion of the pneumococcal vaccine market.

Leading companies operating in the pneumococcal vaccine market are focusing on product innovation to enhance their market position and profitability. For example, in July 2023, Merck & Co. Inc., a US-based pharmaceutical company, introduced the V116 vaccine. V116 is designed to target eight specific serotypes of Streptococcus pneumoniae that are mainly responsible for pneumococcal disease in adults. Compared with existing pneumococcal vaccines, V116 has demonstrated improved immunogenicity across multiple serotypes in adult populations and has shown positive immune responses in both vaccine-naive individuals and those previously vaccinated. The U.S. Food and Drug Administration has granted V116 breakthrough therapy designation, and the vaccine is currently undergoing Phase 3 clinical development.

In December 2024, Sanofi SA, a France-based pharmaceutical company, expanded its collaboration with SK Bioscience Co. Ltd. to further advance the development of its licensed pneumococcal conjugate vaccine. Through this expanded partnership, Sanofi aims to accelerate late-stage development and strengthen its pneumococcal vaccine portfolio by leveraging SK Bioscience's advanced expertise in vaccine development and manufacturing. SK Bioscience Co. Ltd. is a South Korea-based biotechnology company specializing in pneumococcal vaccine research, development, and biomanufacturing.

Major companies operating in the pneumococcal vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, PnuVax Incorporated, SK Bioscience Co Ltd, Bharat Biotech International Ltd, Medicago Inc., Emergent BioSolutions Inc., Valneva SE

North America was the largest region in the pneumococcal vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pneumococcal vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pneumococcal vaccine market consists of sales of vaxneuvance, prevnar 20, pneumococcal conjugate vaccines (PCV)10, and pneumococcal conjugate vaccines (PCV)7. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pneumococcal Vaccine Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses pneumococcal vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pneumococcal vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pneumococcal vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Product Type: Prevnar 13; Synflorix; Pneumovax23; Other Products
2) By Route of Administration: Intravenous; Intramuscular; Subcutaneous
3) By Distribution Channel: Pharmacies; Community Clinics; Public Health Agencies; Other Distribution Channels
4) By End User: Pediatrics; Adults
Subsegments:
1) By Prevnar 13: Pediatric Formulation; Adult Formulation
2) By Synflorix: Pediatric Formulation; Adult Formulation
3) By Pneumovax23: Single-Dose Vials; Pre-Filled Syringes
4) By Other Products: PCV15 (Vaxneuvance); PCV20 (Prevnar 20); Other Regional Pneumococcal Vaccines
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi S.A.; GlaxoSmithKline plc; CSL Limited; Anhui Zhifei Longcom Biopharmaceutical Co. Ltd; Serum Institute of India Private Limited; Walvax Biotechnology Co. Ltd; Biological E Limited; Hualan Biological Engineering Inc.; Beijing Minhai Biotechnology Limited Company; NPO Petrovax Pharm LLC; Vaxcyte Inc.; Panacea Biotec Ltd; PnuVax Incorporated; SK Bioscience Co Ltd; Bharat Biotech International Ltd; Medicago Inc.; Emergent BioSolutions Inc.; Valneva SE
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH4MPVAC01_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Pneumococcal Vaccine Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Pneumococcal Vaccine Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Pneumococcal Vaccine Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Pneumococcal Vaccine Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.3 Artificial Intelligence & Autonomous Intelligence
- 4.1.4 Industry 4.0 & Intelligent Manufacturing
- 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
- 4.2.1 Expansion Of Conjugate Vaccines For Broader Serotype Coverage
- 4.2.2 Increased Focus On Pediatric And Geriatric Immunization Programs
- 4.2.3 Rising Adoption Of Combination And Booster Vaccination Strategies
- 4.2.4 Strengthening Public-Private Partnerships For Immunization Coverage
- 4.2.5 Growth In Preventive Healthcare And National Immunization Schedules

5. Pneumococcal Vaccine Market Analysis Of End Use Industries

5.1 Pediatric Hospitals
5.2 Adult Hospitals
5.3 Community Health Centers
5.4 Government Immunization Programs
5.5 Private Clinics

6. Pneumococcal Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Pneumococcal Vaccine Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Pneumococcal Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Pneumococcal Vaccine Market Size, Comparisons And Growth Rate Analysis
7.3. Global Pneumococcal Vaccine Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Pneumococcal Vaccine Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Pneumococcal Vaccine Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Pneumococcal Vaccine Market Segmentation

9.1. Global Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Prevnar 13, Synflorix, Pneumovax23, Other Products
9.2. Global Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Intravenous, Intramuscular, Subcutaneous
9.3. Global Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels
9.4. Global Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Pediatrics, Adults
9.5. Global Pneumococcal Vaccine Market, Sub-Segmentation Of Prevnar 13, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Pediatric Formulation, Adult Formulation
9.6. Global Pneumococcal Vaccine Market, Sub-Segmentation Of Synflorix, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Pediatric Formulation, Adult Formulation
9.7. Global Pneumococcal Vaccine Market, Sub-Segmentation Of Pneumovax23, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Single-Dose Vials, Pre-Filled Syringes
9.8. Global Pneumococcal Vaccine Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

10. Pneumococcal Vaccine Market Regional And Country Analysis

10.1. Global Pneumococcal Vaccine Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Pneumococcal Vaccine Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Pneumococcal Vaccine Market

11.1. Asia-Pacific Pneumococcal Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Pneumococcal Vaccine Market

12.1. China Pneumococcal Vaccine Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Pneumococcal Vaccine Market

13.1. India Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Pneumococcal Vaccine Market

14.1. Japan Pneumococcal Vaccine Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Pneumococcal Vaccine Market

15.1. Australia Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Pneumococcal Vaccine Market

16.1. Indonesia Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Pneumococcal Vaccine Market

17.1. South Korea Pneumococcal Vaccine Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Pneumococcal Vaccine Market

18.1. Taiwan Pneumococcal Vaccine Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Pneumococcal Vaccine Market

19.1. South East Asia Pneumococcal Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Pneumococcal Vaccine Market

20.1. Western Europe Pneumococcal Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Pneumococcal Vaccine Market

21.1. UK Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Pneumococcal Vaccine Market

22.1. Germany Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Pneumococcal Vaccine Market

23.1. France Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Pneumococcal Vaccine Market

24.1. Italy Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Pneumococcal Vaccine Market

25.1. Spain Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Pneumococcal Vaccine Market

26.1. Eastern Europe Pneumococcal Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Pneumococcal Vaccine Market

27.1. Russia Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Pneumococcal Vaccine Market

28.1. North America Pneumococcal Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Pneumococcal Vaccine Market

29.1. USA Pneumococcal Vaccine Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Pneumococcal Vaccine Market

30.1. Canada Pneumococcal Vaccine Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Pneumococcal Vaccine Market

31.1. South America Pneumococcal Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Pneumococcal Vaccine Market

32.1. Brazil Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Pneumococcal Vaccine Market

33.1. Middle East Pneumococcal Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Pneumococcal Vaccine Market

34.1. Africa Pneumococcal Vaccine Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Pneumococcal Vaccine Market, Segmentation By Product Type, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Pneumococcal Vaccine Market Regulatory and Investment Landscape

36. Pneumococcal Vaccine Market Competitive Landscape And Company Profiles

36.1. Pneumococcal Vaccine Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Pneumococcal Vaccine Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Pneumococcal Vaccine Market Company Profiles
- 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. CSL Limited Overview, Products and Services, Strategy and Financial Analysis

37. Pneumococcal Vaccine Market Other Major And Innovative Companies

Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, PnuVax Incorporated, SK Bioscience Co Ltd, Bharat Biotech International Ltd, Medicago Inc., Emergent BioSolutions Inc., Valneva SE

38. Global Pneumococcal Vaccine Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Pneumococcal Vaccine Market

40. Pneumococcal Vaccine Market High Potential Countries, Segments and Strategies

40.1 Pneumococcal Vaccine Market In 2030 - Countries Offering Most New Opportunities
40.2 Pneumococcal Vaccine Market In 2030 - Segments Offering Most New Opportunities
40.3 Pneumococcal Vaccine Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations
41.2. Currencies
41.3. Historic And Forecast Inflation Rates
41.4. Research Inquiries
41.5. The Business Research Company
41.6. Copyright And Disclaimer